MQ Form 4: 817,260 RSUs awarded to Michael Milotich with clear vesting
Rhea-AI Filing Summary
Michael Milotich, a director and listed as Chief Executive Officer and Chief Financial Officer in the remarks, reported a grant of 817,260 restricted stock units (RSUs) in Marqeta, Inc. (MQ) on 09/15/2025. Each RSU converts into one share of Class A Common Stock. The RSUs carry a $0 price and are shown as directly owned for a total of 817,260 shares following the transaction. Vesting begins with one-twelfth (1/12) vesting on December 1, 2025 and then vests quarterly on March 1, June 1, September 1 and December 1 thereafter until fully vested, subject to continued service. The form was signed by an attorney-in-fact on 09/17/2025.
Positive
- Grant of 817,260 RSUs to reporting person documented, with clear conversion ratio of 1 RSU = 1 share
- Detailed vesting schedule disclosed: 1/12 vest on Dec 1, 2025 then quarterly on March 1, June 1, September 1 and December 1
- Direct ownership of 817,260 Class A shares reported following the transaction
Negative
- None.
Insights
TL;DR: Large RSU award to an insider aligns long-term compensation but represents a material equity grant requiring investor attention.
The filing documents a single, sizeable award of 817,260 RSUs to Michael Milotich with a standard service-based vesting schedule. The award is convertible 1:1 into Class A shares and is recorded at a $0 price, consistent with restricted stock unit treatment. From a governance perspective, such an award ties senior management incentives to stock performance but also increases potential share dilution when vested and settled. The disclosure is straightforward and includes vesting cadence and signer certification.
TL;DR: The grant is a significant equity compensation event; vesting timeline and size are key for pay-for-performance assessment.
This Form 4 reports an equity grant of 817,260 RSUs exercisable into Class A Common Stock on a one-for-one basis, with vesting beginning 12/01/2025 and then quarterly. The $0 price indicates typical restricted units rather than an option. For compensation benchmarking, the absolute size and timing matter for dilution and future share-based expense recognition, and investors should reference proxy and 10-K disclosures for total outstanding equity to assess materiality.